July 19 2016 Issue

1) Zika virus-associated Guillain-Barre Syndrome Variant in Haiti2 e-Pearl topic: Juvenile Huntington Disease3) Topic of the month: Clinical Trials Plenary Session at the AAN meeting about 5-HT6 antagonist as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer diseaseThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Stephen Donahue interviews Dr. Aaron Berkowitz about his paper on Zika virus-associated Guillain-Barre syndrome variant in Haiti. Dr. Ilena George is reading our e-Pearl of the week about juvenile Huntington disease. Dr. Alberto Espay interviews Dr. Alireza Atri about his Clinical Trials Plenary Session at the AAN meeting about 5-HT6 antagonist as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer disease.DISCLOSURES: Dr. Berkowitz receives royalties from the publication of the book: Clinical Pathophysiology Made Ridiculously Simple and the book: The Improvising Mind; received funding for travel from Stevens Institute of Technology; received speaker honorarium from Audio Digest; and received honorarium for recorded CME lecture.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.